Avenacy, a U.S.-based specialty pharmaceutical company, has launched Bortezomib for Injection in the United States, marking its 28th product launch since October 2023. The product, equivalent to VELCADE®, is approved by the FDA for multiple myeloma and mantle cell lymphoma. This launch signals Avenacy's growing role in supplying high-impact injectable medications to clinics and hospitals, relevant for overseas buyers monitoring U.S. oncology injectable supply chains.
Product and market context
Bortezomib for Injection is supplied as a single-dose vial of 3.5 mg per carton. U.S. sales of the drug reached approximately $43 million in the twelve months ending March 2026, according to IQVIA data. The product is indicated for adult patients with multiple myeloma and mantle cell lymphoma, and is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol, and for intrathecal administration.
Packaging and supply chain differentiation
Avenacy emphasizes differentiated packaging and labeling designed to reduce medication selection errors, supporting patient safety in clinical settings. The company will begin shipping to wholesale partners this week. Its supply chain relies on a global network of development and contract manufacturing partners that have passed FDA inspections under current Good Manufacturing Practices (cGMP).
What buyers should watch
For overseas importers and distributors, Avenacy's rapid product launch cadence—28 products in under three years—indicates a reliable pipeline of FDA-approved injectables. The company's focus on oncology injectables and its use of differentiated packaging may appeal to clinics and hospitals seeking to streamline inventory management. Buyers should monitor Avenacy's expansion into additional therapeutic areas and its wholesale distribution partnerships.
Regulatory and channel signals
The product's FDA approval and cGMP-compliant manufacturing partners provide a strong regulatory foundation. Avenacy's U.S. headquarters in Schaumburg, Illinois, and its use of contract manufacturing partners suggest potential for international distribution partnerships. The company's mission to supply critical injectables to acute care hospitals, outpatient clinics, and physician offices aligns with demand in global medical aesthetics and oncology settings.
Source: Read the original report | Published: June 17, 2026